Clinical pharmacokinetics and pharmacodynamics of bromfenac

Bromfenac is a nonsteroidal anti-inflammatory drug whose peak plasma concen tration is reached 0.5 hours after oral administration. Bromfenac binds ext ensively to plasma albumin. The area under the plasma concentration-time cu rve is linearly proportional to the dose for oral doses up to 150 mg. The r elationship between the total plasma and analgesic effect has been establis hed. Only small amounts of bromfenac are eliminated unchanged, with the rem aining drug being biotransformed into glucuronide metabolites which are exc reted in urine and bile. Rapid elimination occurs in healthy individuals (half-life 0.5 to 4.0 h). R enal disease, hepatic disease and aging alter the disposition kinetics of b romfenac, and dosage adjustment may be advisable. Bromfenac modestly decrea ses free phenytoin concentrations. Bromfenac can cause idiosyncratic hepati c toxicity and has been withdrawn by its manufacturer pending further inves tigation of these case reports.